The rationale for combining TMZ with lapatinib relied on the fact that this treatment targets the epidermal growth factor receptor (ErbB1) and the related family member human epidermal growth factor receptor 2/neu (ErbB2), which are both overexpressed on ependymoma tumor cells [36]. Here, EGFR is linked to ependymoma.